TABNAXA Trademark

Trademark Overview

On Wednesday, December 21, 2011, a trademark application was filed for TABNAXA with the United States Patent and Trademark Office. The USPTO has given the TABNAXA trademark a serial number of 85501240. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, February 4, 2022. This trademark is owned by AstraZeneca AB. The TABNAXA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations and substances for the treatment of cardiovascular diseases and disorders, respiratory diseases and disorders, inflammation, infections, gastrointestinal diseases and disorders, and nervous system diseases and disorders
tabnaxa

General Information

Serial Number85501240
Word MarkTABNAXA
Filing DateWednesday, December 21, 2011
Status710 - CANCELLED - SECTION 8
Status DateFriday, February 4, 2022
Registration Number4779731
Registration DateTuesday, July 28, 2015
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 12, 2015

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations and substances for the treatment of cardiovascular diseases and disorders, respiratory diseases and disorders, inflammation, infections, gastrointestinal diseases and disorders, and nervous system diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, February 4, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAstraZeneca AB
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressSödertälje SE-15185
SE
Party NameAstraZeneca AB
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressSödertälje SE-151 85
SE
Party NameAstraZeneca AB
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressSödertälje SE-151 85
SE

Trademark Events

Event DateEvent Description
Friday, February 4, 2022CANCELLED SEC. 8 (6-YR)
Thursday, July 22, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, July 22, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 22, 2021TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Thursday, July 22, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 22, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 22, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, July 28, 2020COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, February 8, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 28, 2015REGISTERED-PRINCIPAL REGISTER
Tuesday, May 12, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 12, 2015PUBLISHED FOR OPPOSITION
Wednesday, April 22, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, April 3, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, April 2, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, April 2, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 2, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 1, 2015TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, October 6, 2014NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Monday, October 6, 2014INQUIRY TO SUSPENSION E-MAILED
Monday, October 6, 2014SUSPENSION INQUIRY WRITTEN
Monday, October 6, 2014SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Wednesday, April 2, 2014NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, April 2, 2014LETTER OF SUSPENSION E-MAILED
Wednesday, April 2, 2014SUSPENSION LETTER WRITTEN
Tuesday, October 1, 2013NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, October 1, 2013LETTER OF SUSPENSION E-MAILED
Tuesday, October 1, 2013SUSPENSION LETTER WRITTEN
Tuesday, October 1, 2013SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Sunday, March 31, 2013NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sunday, March 31, 2013LETTER OF SUSPENSION E-MAILED
Sunday, March 31, 2013SUSPENSION LETTER WRITTEN
Friday, March 29, 2013EXAMINER'S AMENDMENT ENTERED
Friday, March 29, 2013NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, March 29, 2013EXAMINERS AMENDMENT E-MAILED
Friday, March 29, 2013EXAMINERS AMENDMENT -WRITTEN
Monday, October 15, 2012NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, October 15, 2012FINAL REFUSAL E-MAILED
Monday, October 15, 2012FINAL REFUSAL WRITTEN
Monday, October 15, 2012TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 15, 2012CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 2, 2012ASSIGNED TO LIE
Tuesday, October 2, 2012ASSIGNED TO LIE
Monday, September 24, 2012TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 9, 2012ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, July 9, 2012TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, March 28, 2012NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 28, 2012NON-FINAL ACTION E-MAILED
Wednesday, March 28, 2012NON-FINAL ACTION WRITTEN
Tuesday, March 27, 2012ASSIGNED TO EXAMINER
Tuesday, January 3, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, December 24, 2011NEW APPLICATION ENTERED IN TRAM

Related Keywords

tabnaxa disorders diseases substances pharmaceutical preparations treatment gastrointestinal nervous infections system